A recent study from the New York Institute of Technology (NYIT) reveals that many healthcare providers in the U.S. feel they aren’t equipped to talk with patients about medical marijuana. Despite its growing acceptance, many in the medical field report they haven’t received enough education or training to advise patients confidently.
Currently, cannabis is categorized as a Schedule 1 drug in the U.S., meaning it is considered to have a high abuse potential and no recognized medical benefit. However, in 2023, the DHHS recommended moving it to Schedule 3, recognizing its possible use in treating conditions like cancer-related symptoms, infections, neurological issues, and skin disorders.
At present, medical marijuana is legal in 38 states. Of these, 14 have full-scale medical marijuana programs. An additional nine states only permit the use of cannabis products that are low in THC or high in CBD, and only for certain qualifying health conditions. Because of federal regulations, healthcare providers cannot write traditional prescriptions for cannabis. Instead, they may recommend it when patients meet specific criteria, with rules differing significantly from state to state.
Published in Medical Cannabis and Cannabinoids, the NYIT study shows that most doctors, nurses, and other clinical professionals do not feel ready to have informed conversations about cannabis with their patients.
The researchers reviewed 41 separate studies released between 2013 and 2025. These studies included responses from a range of professionals—physicians, trainees, and specialists in various fields—with opinions that often varied depending on their area of practice:
- Doctors working in states where medical cannabis is legal, as well as those with more experience, were typically more at ease discussing and recommending it.
- A majority of obstetricians were not supportive of its use during pregnancy, and pediatricians were reluctant to support it for children.
- Oncologists, primary care doctors, pain specialists, palliative care providers, and emergency physicians generally believe medical marijuana can help treat chronic pain, appetite loss, depression, nausea, and similar issues.
- Many physicians felt that marijuana could pose risks to patients with congenital heart conditions.
- Neurologists still feel there is social stigma around using cannabis for treating epilepsy.
Lead researcher Dr. Maria Pino, a pharmacist and associate professor, noted that as more states loosen cannabis restrictions, medical professionals need to be better educated. “Training healthcare workers on how to responsibly guide patients using medical marijuana is crucial,” she said. “This not only helps patients get proper care, but also reduces stigma around using cannabis for medical needs.”
The study also pointed out a lack of solid scientific research, which makes it harder to create clear, evidence-based guidelines for medical cannabis treatment.
If healthcare professionals are equipped with the knowledge they need to have informed discussions with patients regarding medical marijuana, the entire cannabis industry, including entities like TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) would have valuable allies in helping patients to make informed decisions about using medical marijuana.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN